This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Media
-
MD Anderson Cancer Center Collaborators Publish Peer Reviewed AML Preclinical Study on Zantrene
23 February 2022 – Race Oncology Limited (“Race”) is pleased to announce a researcherteam, led by Professor Borje Andersson and Associate Professor Ben Valdez of the MDAnderson Cancer Center (Texas, USA), have identified a number of additional clinicallytranslatable drug combinations that showed synergy with Zantrene® when tested in AcuteMyeloid Leukaemia (AML) cells. This study1, sponsored…
-
Appointment of Chief Financial Officer
31 January 2022 – Race Oncology Limited (“Race”) is pleased to announce theappointment of Christina Manfre, as Chief Financial Officer. Christina is employed as a partner at PKF Sydney Pty Ltd and will via PKF provideleadership to Race Oncology’s financial analysis, reporting and strategic financial needs.Christina has a wealth of experience working with a diverse…
-
New Independent Study Identifies Activity of Zantrene in Type 2 Diabetes
25 January 2022 – Race Oncology Limited (“Race”) is pleased is pleased to share details of a recent independent scientific publication in the journal Cells, confirming Zantrene® (bisantrene dihydrochloride) is a highly effective inhibitor of the Fat Mass and Obesity associated protein (FTO) with potential utility in Type 2 diabetes1. Type 2 diabetes is characterized…
-
Race Receives $708k R&D Tax Refund
18 January 2022 – Race Oncology Limited (“Race”) is pleased to announce that it hasreceived a $707,557 Research & Development Tax Incentive Refund from the AustralianTaxation Office for the financial year ending 30 June 2021. Race’s Managing Director and CEO, Mr Phil Lynch commented: “The increased refund forFY21 is representative of the enhanced investment we…
-
Saepe quod odio rerum officiis
Omnis possimus omnis sequi omnis iste Quas dolores nihil incidunt facilis fugiat minus Iusto qui aliquam magni dicta ea molestias. Quo itaque sunt et magnam. Ad eveniet aliquam recusandae. Asperiores velit id magnam facilis
-
Race raises full $29.7 million in heavily oversubscribed Share Purchase Plan
21 December 2021 – Race Oncology Limited (“Race”) is pleased to announce that its Share Purchase Plan (SPP) has closed heavily oversubscribed with $43.9m received in applications from 2,340 shareholders. In line with the terms of the SPP, $29.7m will be accepted, with funds to be applied to Race’s “full case” funding scenario, as set…